Merck and Moderna say cancer vaccine shows promise in preventing recurrence of melanoma
Shares of Moderna have doubled after its cancer vaccine trial with Merck met key endpoints.
Evidence dossier
Intelligence passport
Measured timeline
-
Detected
-
Evidence threshold reached
-
Latest coverage observed
-
Peak measured velocity
-
Outcome review added
📍 How it ended
Merck and Moderna reported positive results from a Phase 3 trial of their cancer vaccine, showing it prevented melanoma recurrence. The story quieted without further updates on subsequent developments or regulatory steps.
Epilogue added 88d ago, after coverage quieted.
The coverage curve
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
Where it stands
- Velocity & Diffusion: Coverage exploded across 8 distinct news outlets with 9 published articles, achieving a live velocity of 15.
- Primary Driver: Shares of Moderna have doubled after its cancer vaccine trial with Merck met key endpoints.
- Predictive Outlook: Archynetys algorithmic models forecast this story will fade from trending status over the next 24 hours.
- Source Integrity: Verified strictly against primary headline reporting under zero-hallucination protocols.
The Phase 3 INTerpath-001 trial of Intismeran Autogene Plus KEYTRUDA® has met its endpoints of recurrence-free survival and distant metastasis-free survival in patients with completely resected Stage IIB-IV melanoma. The trial was conducted by Merck and Moderna.
The Denver Post and Yahoo Finance both note that Moderna's stock has surged. Business Wire and The New York Times both report that the vaccine prevents melanoma from returning.
The trial's full results have not yet been published. The specific details of the trial's methodology and patient outcomes are not yet available.
Synthesized by Archynetys from the headlines below under a strict no-invention contract. Updated 90d ago.
Coverage (9)
-
Moderna shares double as cancer vaccine data rekindles investor hopesReuters · 90d ago
-
Moderna Stock Soars on Cancer Vaccine SuccessWSJ · 90d ago
-
Moderna and Merck shares soar on mRNA cancer vaccineAxios · 90d ago
-
MSD and Moderna eye cancer vaccine market debut on Phase III melanoma scoreClinical Trials Arena · 90d ago
-
-
Moderna shares surge after it says its experimental mRNA cancer treatment passed a key testThe Denver Post · 90d ago
-
Moderna Stock Doubles on Cancer Breakthrough: Here’s What It MeansYahoo Finance · 90d ago
-
-
Moderna and Merck Say mRNA Vaccine Prevents Melanoma From ReturningThe New York Times · 90d ago
Answered
What is the name of the cancer vaccine?
The vaccine is called Intismeran Autogene Plus KEYTRUDA®.
What stage of melanoma was the vaccine tested on?
The vaccine was tested on patients with completely resected Stage IIB-IV melanoma.
What are the endpoints that the vaccine met?
The vaccine met the endpoints of recurrence-free survival and distant metastasis-free survival.
How do you expect this trend to evolve over the next 24 hours?
Cast your vote to register reader intelligence on the velocity and trajectory of this coverage.
Topics
Related trends
Pelacarsen, a promising drug for an inherited heart risk, flops, stunning doctors
Promising heart drug fails to prevent heart attacks or stroke, stunning doctors.
Health Canada approves Moderna’s combined COVID, flu shot for some
Health Canada approves Moderna’s combined COVID, flu shot for some adults.
Moderna Swings to Profit, Lifts Outlook as Covid-19 Vaccine Demand Stabilizes
Moderna swings to profit in Q3 2026 as Covid vaccine demand stabilizes and cancer pipeline gains traction.
Herbal supplement linked to decline in excessive alcohol consumption
A phase 2b trial found kudzu extract reduced binge-drinking days by 27% in adults with alcohol use disorder, though experts caution the evidence is too preliminary for clinical use.
Epileptic seizures nearly vanish after people receive experimental gene therapy in their brains
Experimental gene therapy slashes epileptic seizures by up to 92.6% in early human trials, offering hope to patients with drug-resistant epilepsy.
Moderna swings to profit as momentum for cancer vaccine builds
Moderna’s November 6 profit swing, driven by steadied Covid‑19 vaccine demand and a booming cancer‑vaccine pipeline, sent its stock soaring.
Open prediction lab
Can you beat the machine?
Pick tomorrow's top trend, then compare your result with Archynetys's self-graded forecast.
📬 The daily trend digest
The world's top trends, once a day. No spam, one-click unsubscribe.